Bristol-Myers Squibb Seen Beating Q3 Revenue Estimates, RBC Says

• Company profile and ratings snapshot for Bristol-Myers Squibb • US represents 69.1% of net sales; 32,500 employees • Analyst consensus is Outperform with $65.42 average target, ~9.5% upside Bristol-Myers Squibb develops, manufactures and markets pharmaceuticals for cancer, cardiovascular disease, hepatitis, immune disorders and psychiatric conditions. The U.S. accounts for 69.1% of net sales, and the company employs 32,500 people. Composite ratings cover Trader (valuation, EPS revisions, visibility), Investor (fundamentals, valuation, EPS revisions, visibility), Global, and Quality metrics, alongside an MSCI ESG rating of A. Across 28 analysts, consensus is Outperform, with an average target price of $65.42 versus a last close of $59.75 — implying about 9.48% upside.